Abstract
Objective: tititi(1) To evaluate the serum Sclerostin concentration in patients with stage 3,4 chronic kidney titititidisease at Hue Central Hospital. (2) To investigate the relationship between serum Sclerostin concentration tiand CKD-MBD in patients with stage 3,4 CKD at Hue Central Hospital.
Patients and methods: This study used tititian observational analytic method with a cross-sectional design. The samples of this study were 32 stage tifiti3 and 4 CKD patients (fulfilling KDIGO 2012 criteria) who were treated as inpatients at the Department of Nephrology and Musculoskeletal Medicine, Hue Central Hospital from April 2023 to October 2024.
Results: tiOur study included 32 patients (including 16 males, 16 females) with an average age of 52.66 ± 22.97. The titiaverage serum Sclerostin concentration was 1090.629 ± 901.645 pg/ml (47.99 ± 39.67 pmol/L). According fftitito our study, there was no difference in serum Sclerostin concentration when grouped by gender, BMI tigroup, the presence/absence of hypertension, and anemia. However, in terms of age group, Sclerostin tifftitificoncentration tended to increase with age, the difference was statistically significant (p<0.05). Serum titititifitisclerostin concentration did not have any statistically significant correlations with adjusted serum calcium, tiphosphorus, CaxP product and PTH (p>0.05) in patients with stage 3 and 4 CKD. When grouping according tititititito bone mineral disorders in stage 3 and 4 CKD patients, serum sclerostin concentrations had a statistically fifftisignificant difference (p<0.05) between patients with dyscalcemia; however, in the groups with disorders of tititititififfphosphorus, CaxP accumulation and PTH, sclerostin concentrations had no statistically significant difference (p>0.05).
Conclusion: tiSclerostin is one of the new biomarkers related to bone metabolism, proven to tititititiincrease in patients with impaired renal function and the relationship between Sclerostin concentration and fiCKD-MBD is a new issue, needs to be studied and clarified.
| Published | 2025-04-26 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 15 No. 1 (2025) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2025.1.25 | |
| Keywords | bệnh thận mạn, rối loạn xương-khoáng chất bệnh thận mạn, loãng xương, sclerostitin Chronic Kidney Disease, CKD-MBD, osteoporosis, Sclerostitin |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Hue Journal of Medicine and Pharmacy
Pietrzyk B, Smertka M, Chudek J. Sclerostin: tiIntracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders. Adv Clin Exp Med. 2017 Nov 30;26(8):1283–91.
Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and ticommunication—worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019 Nov 1;96(5):1048–50.
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022 Apr;12(1):7–11.
ti4. KDIGO 2017 Clinical Practice Guideline Update for titithe Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017 Jul;7(1):1–59.
ti5. Pura L, Bandiara R, Gondodiputro R. Sclerostin titiSerum Concentration in Patients with Predialysis Ckd Stage 3-5. Indones J Kidney Hypertens. 2018 Oct 18;1.
ti6. Honasoge M, Rao AD, Rao SD. Sclerostin: recent tiadvances and clinical implications. Curr Opin Endocrinol Diabetes Obes. 2014 Dec;21(6):437.
Thambiah S, Roplekar R, Manghat P, Fogelman I, titiFraser WD, Goldsmith D, et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease titiff(CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int. 2012 Jun;90(6):473–80.
ASSOCIATION BETWEEN SCLEROSTIN WITH CALCIUM AND ORGANIC PHOSPHORUS LEVELS IN PREDIALYTIC CHRONIC KIDNEY DISEASE [Internet]. [cited tt2025 Mar 17]. Available from: https://anzsnevents. com/5044/
Zhao B, Chen A, Wang H, Cui J, Sun Y, Xu L, et al. tititiThe relationship between sclerostin and carotid artery tiatherosclerosis in patients with stage 3–5 chronic kidney disease. Int Urol Nephrol. 2020 Jul 1;52(7):1329–36.